Cardinal Health, Inc. (CAH)
Cardinal Health distributes pharmaceuticals and manufactures medical and laboratory products.
- Fiscal year end in SEC snapshot
- June 30
- Annual report period end
- 2026-06-30
The SEC classifies these issuers under “Wholesale-Drugs, Proprietaries & Druggists' Sundries” (SIC 5122). A shared code is a starting point for finding comparable businesses. Product mix, geography and customers can still differ substantially. Read the company descriptions before treating the group as direct competitors.
Align the reporting periods before comparing annual results. Companies with different year ends report different 12-month windows.
| Fiscal year end (SEC) | Companies |
|---|---|
| March 31 | MCK |
| June 30 | CAH |
| September 30 | COR |
Cardinal Health distributes pharmaceuticals and manufactures medical and laboratory products.
Cencora is a pharmaceutical wholesaler distributing drugs and providing specialty and logistics services.
McKesson distributes pharmaceuticals and medical supplies to pharmacies, hospitals, and providers.
Compare Cardinal Health, Inc. and Cencora, Inc.: business context, fiscal calendars and official filings.
Compare Cardinal Health, Inc. and McKesson Corporation: business context, fiscal calendars and official filings.
Compare Cencora, Inc. and McKesson Corporation: business context, fiscal calendars and official filings.
Industry codes and annual filing references come from the SEC submissions snapshot linked to each issuer in our company catalog (snapshot ; newer filings may exist). Only groups with at least three distinct issuers, business descriptions and annual filing links are included. Multiple share classes of one issuer count as one company. This is a coverage directory, not a complete industry census or a ranking of investments.
SEC Standard Industrial Classification code list explains the classification system. Read our research methodology or browse all industry directories.
Financials describe the business. The next question is which assumptions an investment thesis depends on. Explore the member reports below for analysis of catalysts, risks, and what would change the view. $39/month or $249/year.
Members-only research
$39/mo or $249/yr · cancel future renewals anytime · sources included